Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $116.8 million.

  • Syndax Pharmaceuticals' Cash & Equivalents fell 1218.7% to $116.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.8 million, marking a year-over-year decrease of 1218.7%. This contributed to the annual value of $154.1 million for FY2024, which is 4783.81% down from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Cash & Equivalents of $116.8 million as of Q3 2025, which was down 1218.7% from $108.6 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' 5-year Cash & Equivalents high stood at $295.4 million for Q4 2023, and its period low was $57.5 million during Q1 2023.
  • For the 5-year period, Syndax Pharmaceuticals' Cash & Equivalents averaged around $121.7 million, with its median value being $108.6 million (2025).
  • The largest annual percentage gain for Syndax Pharmaceuticals' Cash & Equivalents in the last 5 years was 29726.99% (2023), contrasted with its biggest fall of 6954.97% (2023).
  • Over the past 5 years, Syndax Pharmaceuticals' Cash & Equivalents (Quarter) stood at $222.1 million in 2021, then crashed by 66.52% to $74.4 million in 2022, then soared by 297.27% to $295.4 million in 2023, then plummeted by 47.84% to $154.1 million in 2024, then dropped by 24.19% to $116.8 million in 2025.
  • Its Cash & Equivalents was $116.8 million in Q3 2025, compared to $108.6 million in Q2 2025 and $154.0 million in Q1 2025.